Ann Gramza
Hematology & Oncology · Washington, DCNPI 1760690069
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Eisai Inc. at 56.3% of the total. Reporting peaked in 2023 at $15,722 and has fallen 99.2% since, to $133 in 2024.
Across 33 payments — averaging $1214.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$23K
- Exelixis Inc.$17K
- AstraZeneca$133
Across 75 payments — averaging $9185.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$201K
- Astrazeneca UK Limited$134K
- Merck$92K
- Roche Products Limited$81K
- Genentech, Inc.$70K
- EMD Serono, Inc.$40K
- plus $71K from 6 others
What the payments were for
- Consulting fees$16,60641%
- Speaking & faculty fees$17,89545%
- Travel & lodging$5,32513%
- Food & beverage$2551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 20 | $22,560 |
| Exelixis Inc. | 12 | $17,389 |
| AstraZeneca | 1 | $133 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,081 in reported general payments places this provider in the 80th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.